AbCellera rises as it starts mid-stage trial for menopause drug

Shares of drugmaker AbCellera ABCL.O rise 6.2% to $4.64 in premarket trading

Co says it has started dosing patients in a mid-stage trial for ABCL635, its experimental drug aimed at treating hot flashes and other moderate-to-severe symptoms linked to menopause

Drug aims to ease hot flashes and other moderate-to-severe menopause symptoms, per co

Co's ABCL635 offers non-hormonal alternative for women avoiding hormone therapy

Trial will enroll 80 postmenopausal women; results expected in Q3 2026 - ABCL

As of last close, stock up ~17% over the past year